A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

Hu, Jing; Zhao, Gang; Wang, Hong-Xia; Tang, Lei; Xu, Ying-Chun; Ma, Yue; Zhang, Feng-Chun

doi:10.1186/1756-8722-4-11

Table 2 Regimens of the trials included in this analysis.

From: A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

Trial	Arm	Regimens
Gong JF 2007	Gem/X	Gem 1,000 mg/m² d_1,8; 5-FU 425-600 mg/m² d_1-5, or DDP 30-37.5 mg/m² d_1-2, or Oxa 85-130 mg/m² d₁, or Cap 1 000 mg/m² bid d_1-14, q3w.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
Reni M 2005	PEFG	DDP 40 mg/m² d₁, EPI 40 mg/m² d₁, Gem 600 mg/m² d_1,8, 5-FU 200 mg/m² d_1-28, q4w.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
Gem versus Gem plus fluoropyrimidine
Cunningham D	Gem/Cap	Gem 1,000 mg/m² weekly for 3 weeks; Cap 830 mg/m² bid po for 3 weeks, q4w
2009	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Bernhard J 2008	Gem/Cap	Gem 1,000 mg/m² d_1,8; Cap 650 mg/m² bid po d_1-14, q3w.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Scheithauer	Gem/Cap	Gem 2200 mg/m² d₁, Cap 2500 mg/m² d_1-7, q2w.
W 2003	Gem	Gem 2200 mg/m² d₁, q2w.
Berlin JD 2002	Gem/5-FU	Gem 1,000 mg/m² weekly, 5-FU 600 mg/m² weekly for 3 weeks, q4w.
	Gem	Gem 1,000 mg/m² weekly for 3 weeks, q4w.
Di Costanzo	Gem/5-FU	Gem was combined with 5-FU 200 mg/m² for 6 weeks in the first cycle, followed by a week of rest; then for 3 weeks, q4w.
F 2005	Gem	Gem 1,000 mg/m² weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
Riess H 2005	GFF	Gem 1,000 mg/m², 5-FU 750 mg/m², folinic acid 200 mg/m² d_1,8,15,22, q6w.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
Gem versus Gem plus platinum
Louvet C 2005	Gem/Oxa	Gem 1,000 mg/m² d₁, Oxa 100 mg/m² d₂, q2w.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Poplin E 2009	Gem/Oxa	Gem 1,000 mg/m² d₁, Oxa100 mg/m² d₂, q2w.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
	Gem FDR	Gem 1,500 mg/m² administered as a 150 minutes infusion d_1,8,15, q4w.
Yan ZC 2007	Gem/Oxa	Gem 1,000 mg/m² d₁, Oxa 100 mg/m² d₂, q2w.
	Gem	Gem 1,000 mg/m² d_1,8,15, q4w.
Colucci G 2010	Gem/DDP	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; DDP 25 mg/m² added weekly to Gem.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Colucci G 2002	Gem/DDP	Gem 1000 mg/m² weekly × 7 followed by 2-week rest, DDP 25 mg/m² per week 1 hour before Gem.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 2-week rest, then weekly for 3 weeks, q4w.
Wang XY 2002	Gem/DDP	Gem 1 000 mg/m² d_1,8,15; DDP 60 mg/m² on d₁₅, q4w.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Heinemann V 2006	Gem/DDP	Gem 1,000 mg/m², DDP 50 mg/m² d_1,15, q4w.
	Gem	Gem 1,000 mg/m² d_1,8,15, q4w.
Palmer DH 2007	Gem/DDP	Gem 1000 mg/m² every 7 days for 43 days, followed immediately by DDP 25 mg/m²
	Gem	Gem 1000 mg/m² every 7 days for 43 days
Li CP 2004	Gem/DDP	Gem 1000 mg/m²/week and DDP 25 mg/m²/week × 3 every 4 weeks
	Gem	Gem 1000 mg/m² × 3 every 4 weeks
Kulke MH 2009	Gem/DDP	Gem 1,000 mg/m² d_1,8,15; DDP 50 mg/m² d_1,15, q4w.
	Gem FDR	Gem 1,500 mg/m² at a rate of 10 mg/m²/min d_1,8,15, q4w.
	Gem/Doc	Gem 1,000 mg/m²; Doc 40 mg/m² d_1,8, q3w.
	Gem/CPT-11	Gem 1,000 mg/m²; irinotecan 100 mg/m² d_1,8, q3w.
Viret F 2004	Gem/DDP	Gem 1000 mg/m² d_1,8,15; DDP 75 mg/m² d₁₅, q4w.
	Gem	Gem 1000 mg/m² weekly × 7 followed by 1 week of rest, then weekly for 3 weeks, q4w
Gem versus camptothecin
Stathopoulos GP 2006	Gem/CPT-11	Gem d_1,8; CPT-11 300 mg/m² d₈, q3w.
	Gem	Gem 900 mg/m² d_1,8,15, q4w.
Rocha Lima CM 2004	Gem/CPT-11	Gem 1,000 mg/m² and CPT-11 100 mg/m² given weekly for 2 weeks every 3-week cycle.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Abou-Alfa GK 2006	Gem/Exat	Exatecan 2.0 mg/m² and Gem 1,000 mg/m² were administered on days 1 and 8, q3w.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Gem versus pemetrexed
Oettle H 2005	Gem/Pem	Gem 1,250 mg/m² d_1,8; pemetrexed 500 mg/m² d₈, q3w.
	Gem	Gem 1,000 mg/m² d_1,8,15, q4w.
Gem versus Gem plus targeted therapy
Moore MJ 2007	Gem/Erlo	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Erlotinib 100 or 150 mg/d po
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
Van Cutsem E 2004	Gem/Tipi	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Tipifarnib 200 mg bid po continuously;
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
Philip PA 2010	Gem/C-225	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w;
		Cetuximab 400 mg/m² on week 1, followed by weekly 250 mg/m².
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
Saif MW 2009	Gem/LY	Gem 1000 mg/m² d_1,8,15, q4w; continuously administered LY 600 mg twice daily.
	Gem	Gem 1000 mg/m² d_1,8,15, q4w.
Spano JP 2008	Gem/Axitinib	Gem 1000 mg/m² d_1,8,15, q4w; Axitinib 5 mg twice daily.
	Gem	Gem 1000 mg/m² d_1,8,15, q4w.
Bramhall SR 2002	Gem/Marimastat	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Marimastat 25 mg bid po.
	Gem	Gem 1,000 mg/m² weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Kindler HL 2010	Gem/Bev	Gem 1,000 mg/m² d_1,8,15; Bev 10 mg/kg d_1,15; q4w.
	Gem	Gem 1,000 mg/m² d_1,8,15; q4w.
Richards DA 2006	Gem/CI-994	Gem 1000 mg/m² d_1,8,15; CI-994 6 mg/m² d_1-21; q4w.
	Gem	Gem 1000 mg/m² d_1,8,5; q4w.
Friess H 2006	Gem/Cile	Gem 1000 mg/m² d_1,8,15; Cilengitide 600 mg/m² twice weekly; q3w.
	Gem	Gem 1000 mg/m² d_1,8,15; q3w.
the others
Cascino S 2008	C-225/Gem/DDP	Cetuximab 250 mg/m² weekly, after a loading dose of 400 mg/m2; Gem 1000 mg/m² and DDP 35 mg/m² on d_1,8; q3w.
	Gem/DDP	Gem 1000 mg/m² and DDP 35 mg/m² on d_1,8; q3w.
Vervenne W 2008	Gem/Erlo/Bev	Gem 1,000 mg/m² weekly × 7 during first 8 weeks, then for 3 weeks, q4w.
		Erlotinib 100 mg/d po daily; Bevacizumab 5 mg/kg q2w.
	Gem/Erlo	Gem 1,000 mg/m² weekly × 7 for 7 weeks followed by 1-week rest, then weekly for 3 weeks, q4w; Erlotinib 100 mg/d po daily.
Boeck S 2007	Cap/Oxa	Cap 1000 mg/m² bid d_1-14; Oxa 130 mg/m² d_1.
	Gem/Cap	Gem 1,000 mg/m² d_1,8; Cap 825 mg/m² bid d_1-14
	Gem/Oxa	Gem 1,000 mg/m² d_1,8; Oxa 130 mg/m² d₈

Note: Gem, gemcitabine; DDP, cisplatin; 5-FU, 5-fluorouracil; EPI, epirubicin; CPT-11, irinotecan; Bev, bevacizumab; Oxa, oxaliplatin; Cap, capecitabine; Doc, docetaxel; FDR, fixed dose rate; Exat, exatecan; Tipi, tipifarnib; Erlo, Erlotinib; C-225, cetuximab; Cile, Cilengitide; Bev, bevacizumab; LY, LY293111; UK, unknown; M*, metastatic disease; Gem-X, gemcitabine combined with 5-FU or capecitabine or cisplatin or oxaliplatin.

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com

Journal of Hematology & Oncology

Contact us